Claude Linassier
Overview
Explore the profile of Claude Linassier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chamorey E, Pujalte-Martin M, Ferrero J, Mahammedi H, Gravis G, Roubaud G, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892246
This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that...
2.
Vareille F, Chaumier F, Linassier C, Mallet D, Cancel M
BMJ Support Palliat Care
. 2024 Jun;
PMID: 38871402
No abstract available.
3.
Aubert M, Mathiot L, Vegas H, Ouldamer L, Linassier C, Augereau P, et al.
Oncologist
. 2024 May;
29(7):e910-e917.
PMID: 38768082
Background: In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When...
4.
Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, et al.
Eur J Cancer
. 2024 May;
205:114121.
PMID: 38749111
Introduction: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors...
5.
Guilhem-Ducleon G, Dalban C, Negrier S, Gravis G, Laguerre B, Chevreau C, et al.
Clin Genitourin Cancer
. 2023 Aug;
21(6):643-652.
PMID: 37635052
Background: In metastatic renal clear cell carcinoma (ccRCC), vascular endothelial growth factor receptor (VEGFR) and immune checkpoint are 2 main therapeutic targets. We investigated the impact of duration exposure to...
6.
Orlando V, Drubay D, Lavaud P, Faivre L, Lesaunier F, Delva R, et al.
Clin Genitourin Cancer
. 2023 Jun;
21(5):615.e1-615.e8.
PMID: 37263910
Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases...
7.
Ferrero J, Mahammedi H, Gravis G, Roubaud G, Beuzeboc P, Largillier R, et al.
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839973
Abiraterone acetate (AA) is the first-in-class of drugs belonging to the second-generation of agents inhibiting androgen neosynthesis in advanced prostate cancer. A cumulative experience attests that germinal gene polymorphisms may...
8.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, et al.
Eur J Cancer
. 2022 Dec;
180:21-29.
PMID: 36527973
Background: Immune checkpoint inhibitor-based combination therapy (ICI-based combination) is a new standard of care for metastatic clear cell renal cell carcinoma (mRCC) in the frontline setting. Patients with poor performance...
9.
Pobel C, Laurent E, Florence A, Fromont G, Calais G, Narciso B, et al.
Clin Genitourin Cancer
. 2022 May;
20(5):495.e1-495.e9.
PMID: 35562276
Introduction: The overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients has improved since 2011 with the use of novel hormonal agents (NHAs). The incidence of brain metastases (mets)...
10.
Cancel M, Fromont G, Blonz C, Chevreau C, Rioux-Leclercq N, Laguerre B, et al.
Eur J Cancer
. 2021 Oct;
158:1-11.
PMID: 34619467
Background: Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib...